Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;17(6):1037-43.
doi: 10.3201/eid/1706.100358.

Cefepime-resistant Pseudomonas aeruginosa

Ehimare Akhabue  1 , Marie Synnestvedt, Mark G Weiner, Warren B Bilker, Ebbing Lautenbach
Affiliations

Cefepime-resistant Pseudomonas aeruginosa

Ehimare Akhabue et al. Emerg Infect Dis. 2011 Jun.

Abstract

Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case-control study in Philadelphia, Pennsylvania. Among 2,529 patients hospitalized during 2001-2006, a total of 213 (8.4%) had cefepime-resistant P. aeruginosa infection. Independent risk factors were prior use of an extended-spectrum cephalosphorin (p<0.001), prior use of an extended-spectrum penicillin (p = 0.005), prior use of a quinolone (p<0.001), and transfer from an outside facility (p = 0.01). Among those hospitalized at least 30 days, mortality rates were higher for those with cefepime-resistant than with cefepime-susceptible P. aeruginosa infection (20.2% vs. 13.2%, p = 0.007). Cefepime-resistant P. aeruginosa was an independent risk factor for death only for patients for whom it could be isolated from blood (p = 0.001). Strategies to counter its emergence should focus on optimizing use of antipseudomonal drugs.

PubMed Disclaimer

Figures

Figure
Figure
Prevalence of infection with cefepime-resistant Pseudomonas aeruginosa, Philadelphia, PA, USA, 2001–2006. p = 0.9946 for trend.
See this image and copyright information in PMC

References

    1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–54. 10.1086/432803 - DOI - PubMed
    1. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis. 2000;30:454–60. 10.1086/313710 - DOI - PubMed
    1. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents. 2004;24:111–8. 10.1016/j.ijantimicag.2003.12.019 - DOI - PubMed
    1. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest. 1996;109:1019–29. 10.1378/chest.109.4.1019 - DOI - PubMed
    1. Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest. 2004;125:607–16. 10.1378/chest.125.2.607 - DOI - PubMed

Publication types

LinkOut - more resources